Date published: 2025-10-2

1-800-457-3801

SCBT Portrait Logo
Seach Input

Medroxyprogesterone 17-Acetate (CAS 71-58-9)

0.0(0)
Write a reviewAsk a question

Alternate Names:
MAP; Clinovir; Depo-Provera; Farlutal; Nidaxin; Oragest; Prodasone; Provera; Veramix
Application:
Medroxyprogesterone 17-Acetate is a synthetic progesterone receptor agonist
CAS Number:
71-58-9
Purity:
≥98%
Molecular Weight:
386.52
Molecular Formula:
C24H34O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Medroxyprogesterone 17-acetate is used in biological research to understand hormonal regulation and endocrine system disorders. In laboratory applications, scientists employ this compound to study its influence on gene expression, particularly genes that are responsive to progesterone. This has implications for understanding cellular growth and differentiation processes. Researchers also utilize medroxyprogesterone 17-acetate to explore its role in the modulation of steroid receptor function, which has been an area of interest in endocrinology and reproductive biology. Additionally, it is instrumental in examining the mechanisms of hormone signaling pathways and their effects on various tissues, offering insights into the intricate network of hormonal interactions within the body.


Medroxyprogesterone 17-Acetate (CAS 71-58-9) References

  1. Medroxyprogesterone acetate exacerbates glutamate excitotoxicity.  |  Nilsen, J., et al. 2006. Gynecol Endocrinol. 22: 355-61. PMID: 16864144
  2. Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression.  |  Tanaka, Y., et al. 2008. Menopause. 15: 442-53. PMID: 18202593
  3. Medroxyprogesterone acetate in the management of cancer cachexia.  |  Madeddu, C., et al. 2009. Expert Opin Pharmacother. 10: 1359-66. PMID: 19445562
  4. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.  |  Tamauchi, S., et al. 2018. J Obstet Gynaecol Res. 44: 151-156. PMID: 29121428
  5. Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer.  |  Mu, N., et al. 2018. Oncol Rep. 39: 2015-2021. PMID: 29393479
  6. Simultaneous TLC-densitometric determination of tamoxifen citrate and medroxyprogesterone acetate and UV-degradation kinetic study of medroxyprogesterone acetate.  |  Saleh, GA., et al. 2018. Biomed Chromatogr. 32: e4366. PMID: 30120785
  7. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.  |  Vinogradova, Y., et al. 2019. BMJ. 364: k4810. PMID: 30626577
  8. The 11α-hydroxylation of medroxyprogesterone acetate by Absidia griseolla var. igachii and Acremonium chrysogenum.  |  Ghasemi, S., et al. 2019. Steroids. 149: 108427. PMID: 31228485
  9. Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi.  |  Zia, Y., et al. 2019. Contraception. 100: 402-405. PMID: 31374188
  10. A meta-analysis of the efficacy of progestin-primed ovarian stimulation with medroxyprogesterone acetate in ovulation induction in poor ovarian responders.  |  Cai, R., et al. 2021. J Gynecol Obstet Hum Reprod. 50: 102049. PMID: 33387677
  11. Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial.  |  Mittal, M., et al. 2022. Maturitas. 161: 18-26. PMID: 35688490
  12. Medroxyprogesterone Acetate for Abnormal Uterine Bleeding Due to Ovulatory Dysfunction: The Effect of 2 Different-Duration Regimens.  |  Bender, RA. 2022. Med Sci Monit. 28: e936727. PMID: 35746846
  13. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.  |  Kawaguchi, H., et al. 2023. Jpn J Clin Oncol. 53: 203-211. PMID: 36484305
  14. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis.  |  Blei, F., et al. 1993. J Cell Physiol. 155: 568-78. PMID: 7684043

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Medroxyprogesterone 17-Acetate, 500 mg

sc-205744
500 mg
$66.00

Medroxyprogesterone 17-Acetate, 1 g

sc-205744A
1 g
$97.00